Trial reportOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2009
1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells.
Trial report in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials.PloS one · 2013Pooled it
- Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.Human immunology · 2010Trial
- Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy.Research (Washington, D.C.) · 2026Review
- Beyond Conventional Treatments: The Role of Complementary Therapies in Head and Neck Cancer.Cancers · 2025Review
- Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.Molecular cancer · 2025Review
- The vitamin DFrontiers in immunology · 2025Review
- Role of Vitamin D in Head and Neck Cancer-Immune Function, Anti-Tumour Effect, and Its Impact on Patient Prognosis.Nutrients · 2023Review
- Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.Signal transduction and targeted therapy · 2021Review
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review.Journal of clinical and translational research · 2021Review
- The role of vitamin D in head and neck cancer.Laryngoscope investigative otolaryngology · 2020Review
- 1α, 25 Dihydroxyvitamin D (1,25(OH)The Journal of steroid biochemistry and molecular biology · 2020Article
- PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.BMC cancer · 2019Article
- MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation.Frontiers in immunology · 2019Review
- Influence of vitamin D on cancer risk and treatment: Why the variability?Trends in cancer research · 2018Article
- Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.Journal of leukocyte biology · 2017Review
- The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.Journal of leukocyte biology · 2017Review
- Targeting Myeloid-Derived Suppressor Cells in Cancer.Advances in experimental medicine and biology · 2017Review
- Improving cancer immunotherapy by targeting the STATe of MDSCs.Oncoimmunology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesPrior studies showed that immune inhibitory CD34(+) progenitor cells, whose numbers are increased in head and neck squamous cell carcinoma (HNSCC) patients, can be differentiated into immune stimulatory dendritic cells by culture with 1alpha,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)). This was extended to a pilot study to diminish intratumoral levels of CD34(+) progenitor cells by inducing their maturation into dendritic cells with 1,25(OH)(2)D(3). STUDY
designNewly diagnosed HNSCC patients were untreated for 3 weeks or received 3 weeks of 1,25(OH)(2)D(3) treatment befoer surgical treatment. SUBJECTS AND
methodsHNSCC tissue was collected by biopsy from six patients who had no prior 1,25(OH)(2)D(3) treatment and at the time of surgical treatment from six untreated patients and 11 patients who completed 1,25(OH)(2)D(3) treatment. Tissues were analyzed by immunohistochemistry for levels of CD34(+) cells and dendritic cells.
resultsAfter 1,25(OH)(2)D(3) treatment, intratumoral levels of CD34(+) cells and levels of immature dendritic cells declined. However, levels of intratumoral mature dendritic cells increased. Clinical effects of 1,25(OH)(2)D(3) treatment are premature to analyze.
conclusionsTreatment of HNSCC patients with 1,25(OH)(2)D(3) reduced levels of immune inhibitory CD34(+) cells while increasing maturation of dendritic cells. This supports added studies to determine the effect of 1,25(OH)(2)D(3) on intratumoral immune competence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.